Objective: This study aims to estimate the prevalence and predictors of moderate/severe poor sleep in relation to the final menstrual period (FMP) in midlife women.
O ne of the most common complaints of midlife women is poor sleep. About 30% of adults have one or more symptoms of insomnia, according to the American Academy of Sleep Medicine and population-based studies. 1, 2 Poor sleep is more prevalent in women, with sex differences emerging around menarche and further increasing in midlife. 3<5 Midlife sleep difficulties are often attributed to symptoms of menopause. Poor sleep is clearly associated with hot flashes, the cardinal symptom of menopause, 6, 7 but evidence indicating that biological decline in ovarian function has direct effects on sleep is limited and controversial. 8, 9 Furthermore, a time course of poor sleep relative to the final menstrual period (FMP), the primary marker of ovarian senescence, has not been identified.
We previously evaluated poor sleep in the early years of the Penn Ovarian Aging Study cohort, when participants were premenopausal and had regular menstrual cycles. 10, 11 At that time, the prevalence of moderate/severe poor sleep was approximately 17%, but the subsequent time course of poor sleep in relation to the FMP could not be determined. Data are now available to estimate the pattern of poor sleep relative to natural menopause. We hypothesized that moderate/severe poor sleep was associated with biological changes in ovarian aging, with a pattern of increasing poor sleep in the years leading to the FMP, a peak around the FMP, and a decrease in the years after menopause. We also hypothesized that the severity of poor sleep at premenopausal baseline predicted poor sleep across the menopausal transition. An additional objective was to evaluate possible risk factors for poor sleep, including hot flashes, anxiety, depression, perceived stress, race, age at menopause, body mass index, and smoking. Longitudinal associations between reproductive hormone levels as markers of the menopausal transition (estradiol, folliclestimulating hormone [FSH] , and inhibin B) and poor sleep were also evaluated.
METHODS

Study participants
The study evaluated 255 women in the Penn Ovarian Aging Study cohort who reached natural menopause during a 16-year follow-up period (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) . To address our primary aim of estimating the risk of poor sleep in relation to the FMP, we included only the participants who reached natural menopause. Comparisons of study variables at baseline between the sample and the remainder of the cohort who were not observed to reach natural menopause during the follow-up period (n = 181) showed no significant differences in study variables, with the exception of age, which was older in the study group at baseline (42.2 vs 40.4 y; P G 0.001).
The original cohort of 436 women was randomly identified by telephone digit dialing in Philadelphia County, PA, using stratified sampling to obtain equal numbers of African-American and white women, as previously described. 10 At enrollment, all women were premenopausal (with regular menstrual cycles of 22-35 d for the previous three cycles), were aged 35 to 48 years, and had an intact uterus and at least one ovary. Exclusion criteria at enrollment included current use of any hormonal or psychotropic medications, alcohol or drug abuse, major psychiatric disorder in the past year, pregnancy or breast-feeding, uncontrolled hypertension, and serious health problems known to compromise ovarian function. The Institutional Review Board of the University of Pennsylvania approved the study, and all participants provided a written informed consent form.
Study design
After cohort enrollment, follow-up assessments were conducted for 16 years at intervals of approximately 9 months and then annually. Study data were collected at two in-home visits, which were timed with the early follicular phase of the menstrual cycle (days 2-6) in two consecutive menstrual cycles (or approximately 1 month apart in women without menstrual cycle) for 14 assessment periods. Assessments 15 to 16 were conducted by telephone interview. The study was described to participants as a general women's health study. Trained research interviewers obtained menstrual dates, structured interview data on overall health, blood samples for hormone assays, and anthropometric measures. Participants completed a set of validated self-report measures to assess health and other behavioral measures of the study at each assessment period.
Study variables
The primary outcome variable was moderate/severe poor sleep, which was included in a validated menopausal symptom questionnaire that was administered at enrollment and at each of the 16 years of follow-up. 12 The interviewer asked, BHave you experienced trouble sleeping in the past month?[ Further queries determined the frequency and severity (1, mild; 2, moderate; 3, severe) of poor sleep. After inspection of response distribution for the severity of poor sleep, a threelevel variable was created for moderate/severe, mild, and no poor sleep. Validity was evaluated by factor analysis conducted in the cohort, which indicated a high correlation of the sleep item with the sleep quality factor score derived from the St Mary's Sleep Questionnaire (r = 0.83). 11 The sleep item was previously used as the primary outcome measure in studies in the cohort, 10 supported by data showing that sleep quality was a better marker than sleep quantity for assessing general health and debilitating feelings such as depression, fatigue, tension, and stress. 13 Time in years (from Q11 y before FMP to Q11 y after FMP) was evaluated in relation to the FMP, which was identified after 12 months or more of no menstrual bleeding and was designated as time 0 for each participant. This allowed longitudinal evaluation of within-woman changes in poor sleep each year before the FMP (up to, but not including, time 0) and each year after the FMP.
Covariate selections were based on previously identified associations with poor sleep and the aims of this study. The variables included age, race (self-reported as African American or white), body mass index (G30 kg/m 2 , Q30 kg/m 2 ), current smoking (yes, no), alcohol use one or more times weekly (yes, no), currently employed (yes, no), education (high school or less, more than high school), and history of depression (yes, no) as identified at cohort enrollment by medical history interview or by the Primary Care Evaluation of Mental Disorders interview. 14 Anxiety, depressed mood, and perceived stress were assessed at each assessment period using validated self-report questionnaires: Zung Anxiety Index, 15 Center for Epidemiologic Studies Depression Scale, 16 and Perceived Stress Scale. 17 Each scale provided a continuous total score, with higher scores indicating more symptoms. The severity of hot flashes was reported by the participants at each assessment period using the validated menopausal symptom list embedded in the structured interview questionnaire. 12 At each follow-up, the interviewer asked whether hot flashes/night sweats occurred in the past month, whether they occurred in the past year, and the severity of hot flashes/night sweats (0, none; 1, mild; 2, moderate; 3, severe). Response distributions for the severity of hot flashes/night sweats were inspected, and a dichotomous variable termed Bhot flashes[ (moderate/severe, mild/none) was used in analysis.
Blood samples were collected at each study visit (providing a possible maximum of 28 samples per woman), centrifuged, and frozen in aliquots at j80-C. Assays were conducted in batches, which included four visits per participant, to reduce within-woman variability resulting from assay conditions. Assays of estradiol and FSH were conducted in the Clinical and Translational Research Center of the University of Pennsylvania using Coat-A-Count commercial kits (Siemens, Deerfield, IL). All assays were performed in duplicate and repeated if values differed by greater than 15%. Interassay and intra-assay coefficients of variation were less than 5%. Dimeric inhibin B was assayed at periods 11 to 14 using enzyme-linked immunosorbent kits (Diagnostic Systems, Webster, TX). The intra-assay and interassay coefficients of variation were 3.5% to 4.6% and 6.3% to 7.6%, respectively. The lower limit of detection was 15 pg/mL. Dimeric inhibin B at periods 1 to 10 was measured from serum in the laboratory of Patrick Sluss, PhD, at the Massachusetts General Hospital (Boston, MA) using a sensitive two-site nonisotopic immunoassay (Oxford BioInnovation, London, UK). The intra-assay and interassay coefficients of variation were less than 8% and less than 20%, respectively, for concentrations of 50 to 500 pg/mL. The lower limit of detection was 15 pg/mL.
Statistical analysis
Longitudinal evaluations of the 255 participants provided 3,399 responses to the item assessing poor sleep. The prevalence of moderate/severe poor sleep was calculated for each year before and after the FMP and compared with prevalence at the FMP (time 0). Generalized linear mixed-effects regression models for repeated measures used all available data from each participant to estimate bivariable and multivariable associations with moderate/severe poor sleep. All models used generalized estimating equation variance estimates for statistical tests on regression coefficients to adjust for repeated observations from each participant in a robust fashion. 18 The models were adjusted for time, which was defined in three segments relative to the FMP: premenopause (from Q11 y to, but not including, the FMP); FMP to 3 years after the FMP; and late postmenopause (Q3 y after the FMP). These cutoff points were previously identified based on data in the cohort 19 and were consistent with the cutoff points suggested for early and late postmenopause in the revised Stages of Reproductive Aging Workshop + 10 staging. 20 A secondary cutoff point at 6 years after the FMP was evaluated with similar results.
Covariates were defined a priori and added singly to the model with time and interaction with time. All time-varying covariates were treated as such in modeling. Hypothesized interactions with time were evaluated for severity of poor sleep at baseline, hot flashes, and mood variables. Covariates that were associated with moderate/severe poor sleep at P e 0.20 were included in multivariable models to determine their independent contributions to the outcome of moderate/severe poor sleep. Inclusion in the final multivariable models was guided by whether each variable remained statistically significant at P e 0.05 or modified other significant associations by 15% or more. Race and age at FMP were not significant but were retained in the final models because of the study design. Hormone levels were modeled using natural log transformations to reduce the influence of large values. The participant mean of the two hormone measures obtained at each assessment period was used in analysis. Odds ratio (OR) estimates for hormones are presented per one-unit (SD) change. Exogenous hormone use was an exclusion criterion at enrollment in the cohort; hormone use during follow-up was low, and only observations at times of use were omitted in analysis. Hysterectomy was an exclusion criterion at enrollment; women who had a hysterectomy after enrollment and before natural menopause were excluded from this study. The few observations of pregnancy or breast-feeding during the study were omitted from analysis only at times of occurrence; data for these participants before and after these events were retained.
Statistical power calculations were computed using STATA version 13 (STATA Corp, College Station, TX). Assumptions were based on data in the cohort and included a 30% prevalence of poor sleep for the unexposed or low-risk group, an average of 13 repeated measures per participant, a type I > error of 5%, and a within-woman correlation of 0.28. Given these assumptions, the current study had 80% power to detect an OR of 1.5 or higher for risk factors with a low prevalence (20%). The detectible OR was 1.39 for risk factors with a prevalence of 30% and was even lower for risk factors with prevalence greater than 30%. All analyses were conducted using SAS version 9.3 statistical package (SAS Inc, Cary, NC). Statistical tests were two-sided, with P e 0.05 considered significant.
RESULTS
Sample description
The 255 participants who reached menopause provided a mean of 13.3 outcome reports per participant. At premenopausal baseline, 28% of the participants reported moderate/severe poor sleep, 16% reported mild poor sleep, and 56% reported no poor sleep. In repeated assessments during the 16-year follow-up, 82.4% (210 of 255) of the participants ever reported moderate/ severe poor sleep, 27 women (10.5%) reported only mild levels of poor sleep, and 18 women (7.1%) never reported poor sleep. The mean (SD) age was 42.16 (3.38) years at baseline and 51.47 (3.32) years at the FMP; 49% of the participants were African American and 51% were white ( Table 1) .
Prevalence of poor sleep around menopause
The annual prevalence of moderate/severe poor sleep primarily ranged from 28% to 35% and did not significantly differ from the FMP in any study year (P = 0.72; Fig. 1 ). The prevalence was 34% at the FMP; prevalence remained above 30% in each study year until late postmenopause, when poor sleep decreased slightly but not significantly.
Stratification of sleep status at premenopausal baseline to predict poor sleep
Stratification of sleep status reported by the participants at premenopausal baseline strongly predicted poor sleep in the years around the FMP. Women with moderate/severe poor sleep at baseline (28% of the sample) were approximately 3.5 times more likely to have moderate/severe poor sleep around the FMP than women who had no poor sleep at baseline in adjusted analysis (OR, 3.58; 95% CI, 2.50-5.11; P G 0.0001); women with mild poor sleep at baseline (16% of the sample) were approximately 1.5 times more likely to have moderate/severe poor sleep around the FMP (OR, 1.57; 95% CI, 0.99-2.47; P = 0.053; Table 2 ).
The percentage of poor sleepers in each time segment of the menopausal transition is shown for each baseline severity group in Figure 2 . The greatest proportion of moderate/severe poor sleepers around menopause comprised women who reported moderate/severe poor sleep at premenopausal baseline, with a prevalence of 54% averaged during the 11 years before the FMP, 47% averaged during the years around the FMP (FMP to 3 y), and 44% averaged during the later years postmenopause (3-11 y postmenopause). Among women who reported no poor sleep at premenopausal baseline, 25% had moderate/severe poor sleep averaged during the 11 years before the FMP, 26% had moderate/severe poor sleep averaged during the years around the FMP, and 25% had moderate/severe poor sleep averaged during the later years postmenopause. In this group, the prevalence of poor sleep was flat during the menopausal transition, with no significant increase around the FMP. Among women with mild poor sleep in premenopause, 32% had moderate/severe poor sleep averaged during the 11 years before the FMP, 43% had moderate/severe poor sleep averaged during the years around the FMP (FMP to 3 y), and 35% had moderate/severe poor sleep averaged during the later years postmenopause (3-10 y postmenopause). Only in this last subgroup was there a significant increase in poor sleep around the FMP, which accounted for the interaction between baseline severity of poor sleep and moderate/ severe poor sleep relative to the FMP (P = 0.038, as shown in Table 3 ).
The analyses were repeated to determine whether a later cutoff point for postmenopausal time relative to the FMP (ie, 6 y postmenopause) altered the findings. The results were similar to those shown.
Hot flashes and poor sleep
The association of moderate/severe hot flashes with poor sleep relative to the FMP was highly significant in adjusted The mean (SD) score for community-based adult women is 25.6 (8.2). c The standard cutoff point for high depressive symptoms is 16 or higher. analysis (OR, 1.79; 95% CI, 1.14-2.21; P G 0.0001; Table 2 ). This is illustrated in Figure 3 , which shows that hot flashes increased around the FMP in each subgroup defined by sleep status at baseline. There was no significant interaction between hot flashes and baseline sleep status (P = 0.25), indicating that hot flashes contributed to poor sleep similarly in each subgroup. There was also no significant interaction between hot flashes and time relative to menopause (P = 0.69), indicating that hot flashes contributed to poor sleep similarly in each period before, around, and after the FMP (interaction P = 0.69). Figure 3 also shows that poor sleep occurred in the absence of hot flashes in all subgroups.
Other significant risk factors for moderate/severe poor sleep during the menopausal transition included anxiety (P G 0.0001) and perceived stress (P = 0.016) in adjusted analysis ( Table 2 ). The significant interaction between perceived stress and time indicated that the greatest impact of stress on poor sleep occurred in the period before the FMP.
The hypothesized covariates race, education, body mass index, employment, alcohol use, smoking, and age at FMP were not associated with moderate/severe poor sleep in either adjusted or unadjusted analysis. Hormone associations with poor sleep were not significant. This was possibly attributable to the inclusion of time in these models, which reflected hormone changes in the same time interval.
DISCUSSION
In this sample of midlife women, the annual prevalence of moderate/severe poor sleep remained at around 30% throughout the menopausal transition, notably similar to the 30% prevalence of insomnia symptoms among adults in other populationbased studies. 1, 2 This yearly prevalence of poor sleep was relatively flat throughout the transition years, with no significant differences in any year relative to the FMP. Premenopausal sleep status was the strongest predictor of moderate/severe poor sleep in the menopausal transition. Moderate/severe poor sleepers before the menopausal transition continued to report moderate/severe poor sleep throughout the menopausal transition, whereas women who did not have poor sleep before the menopausal transition had the lowest risk of poor sleep in the menopausal transition. These novel findings indicated that only one subgroup, which reported mild sleep problems at premenopausal baseline, had a significant increase in poor sleep in the years around the FMP, suggesting a menopauserelated form of sleep disturbance for a small Bat-risk[ group of midlife women.
Hot flashes contributed strongly to poor sleep regardless of sleep status before the menopausal transition. This association was previously identified in studies of subjectively reported hot flashes, 4,6,10,21 although it was not found when both factors were measured physiologically, 22 and the association remains controversial. In a large cross-sectional study where severe hot flashes were associated with chronic insomnia, approximately half of the women indicated that insomnia preceded menopause. 23 Researchers concluded that menopausal hot flashes influenced insomnia but that other factors, such as chronic pain and poor health, were important contributors regardless of menopause status. Other studies that reported a high prevalence of poor sleep quality in midlife women also found that symptoms occurring in premenopause were strongly associated with poor sleep 24 but that the influences of age and menopause were modest. 24, 25 Anxiety and perceived stress were significantly associated with poor sleep, although the causal direction of these associations remains an open question. Anxiety was identified as the strongest predictor of poor sleep quality in previous studies. 26, 27 Depression was a risk factor for poor sleep but was not significant in adjusted analysis. Most participants were not clinically depressed, and the measure of depression was highly correlated with anxiety, which had the stronger association with poor sleep in this study.
Reproductive hormone levels were not associated with poor sleep, as was found in some studies but not in others, 28, 29 suggesting that hormone levels were not strongly associated with poor sleep in healthy midlife women. However, the lack of association in this study could also be attributable to our models, which included time relative to the FMP that reflected changing hormone levels in the menopausal transition. Reports of associations between poor sleep and hormone levels were significant when hormones were modeled without the inclusion of time periods. 5, 10, 11 In our earlier reports on associations between menopause status, hormone levels, and sleep quality, we observed that lower estradiol levels in women aged between 45 and 49 years were associated with poorer sleep quality at baseline assessment 10 and that lower levels of inhibin B, a marker of menopause status, were an independent predictor of sleep difficulty in an 8-year follow-up study. 11 In another report that did not model time periods, early-follicular-phase 
FIG. 2.
Percentage of observations of poor sleep relative to the final menstrual period (FMP), by severity of poor sleep at premenopausal baseline. The model included time defined in three segments (from Q11 y before, but not including, the FMP; FMP to 3 y after the FMP; Q3 y after the FMP); baseline sleep severity (three groups); moderate/severe hot flashes (yes, no); and interaction of baseline sleep severity and hot flashes (P = 0.038). Odds ratios are shown in Table 3 . estradiol levels and a more rapid rate of change in FSH were associated with less favorable sleep quality in the early menopausal transition. 30 Limitations to consider include the subjective report of poor sleep, which rated general sleep quality as perceived by the participants. The validity of the sleep item was previously demonstrated and had a high correlation with a standard measure of sleep quality. 10, 11 Validity was further supported by findings indicating that the prevalence of moderate/severe poor sleep reported by the participants was nearly identical to the prevalence of symptomatic insomnia among adults, as defined by the American Academy of Sleep Medicine. 1 However, the sleep measure did not indicate diagnoses of sleep disorders, such as sleep-disordered breathing, and did not differentiate between different patterns of sleep difficulties (eg, difficulty falling asleep vs midsleep awakenings vs early morning awakenings). We were unable to evaluate possible conditions underlying sleep disturbances or whether the types of complaints associated with poor sleep changed during the reporting period. Furthermore, the data were not sufficient to control for the use of medications related to sleep in these models.
It is possible that including women who had sleep difficulties at premenopausal baseline obscured information about poor sleep that first occurred in the menopausal transition. Further studies evaluating sleep disturbances that first occur in the menopausal transition may identify whether there is a menopause-specific form of sleep disturbance. It is also possible that estradiol assays with a detectable limit lower than that measured by standard commercial assays would provide different results. However, the preponderance of observations in this study occurred before the FMP when estradiol levels were well above detectible limits, with only a small proportion of observations in late postmenopause, suggesting that more precise measures of the lowest estradiol levels would not change these nonsignificant results. This study also could not address the impact of hormone therapy or surgical menopause on sleep quality. Another study found that women using hormone therapy did not have significantly better sleep compared with those who did not use hormone therapy, 31 and further studies addressing these conditions are important for clinical care. Residual confounding caused by potential predictors of sleep quality (such as physical activity and other health and behavioral factors) that may have a significant impact on sleep quality is another limitation of this study. These findings are based on a population-based cohort of African-American and white urban women who were in generally good health and may not be generalizable to all midlife women, particularly those with major health problems that were not represented in this cohort.
The strength of this report is the longitudinal evaluation of poor sleep, commencing in premenopause and extending into the postmenopausal years for all participants. This provided identification of the FMP with minimal recall bias and permitted analysis of sleep quality relative to the FMP to determine whether the pattern of poor sleep was associated with this marker of menopause. The population-based cohort was randomly identified and stratified to have similar numbers of African-American and white women for analysis of racial associations. The measures of poor sleep, hormones, and covariates of the study were repeated annually to provide concurrent assessments at premenopausal baseline and throughout the follow-up years.
CONCLUSIONS
Clinicians can expect many midlife women to report sleep difficulties. However, clinicians should consider that poor sleep is not simply caused by menopause or hot flashes, given the evidence that premenopausal sleep status is the strongest predictor of poor sleep in the menopausal transition. Hot flashes are strongly associated with poor sleep as expected, but a large proportion of poor sleep in the menopausal transition occurs without hot flashes. The common perception that poor sleep is associated with ovarian decline around menopause may pertain to only a small at-risk subgroup of women who have mild complaints at premenopausal baseline that worsen around the FMP. Clinicians should obtain information on whether the onset of poor sleep occurs before the menopausal transition and information on the severity and duration of poor sleep to formulate the most effective treatment strategies. Further studies evaluating causes and treatments are needed to unravel this multifactorial problem and to improve sleep health in midlife women.
